Natixis Geron Corp Transaction History
Natixis
- $17.6 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding GERN
# of Institutions
275Shares Held
491MCall Options Held
1.87MPut Options Held
690K-
Black Rock Inc. New York, NY46.6MShares$189 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY44.1MShares$180 Million3.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA32.4MShares$132 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA32.3MShares$131 Million2.04% of portfolio
-
State Street Corp Boston, MA29MShares$118 Million0.01% of portfolio
About GERON CORP
- Ticker GERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 377,819,008
- Market Cap $1.54B
- Description
- Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...